| Summary of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share |
The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for the three and nine months ended September 30, 2026 and 2025, as the result would be anti-dilutive:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Outstanding stock options |
|
639,693 |
|
|
|
453,385 |
|
|
|
639,693 |
|
|
|
453,385 |
|
Outstanding restricted stock units |
|
449,854 |
|
|
|
336,704 |
|
|
|
449,854 |
|
|
|
336,704 |
|
Warrants to purchase common stock associated with the April 2022 public offering |
|
1,875,003 |
|
|
|
1,875,003 |
|
|
|
1,875,003 |
|
|
|
1,875,003 |
|
Warrants to purchase common stock associated with the March 2026 Private Placement |
|
5,437,464 |
|
|
|
— |
|
|
|
5,437,464 |
|
|
|
— |
|
Warrants to purchase common stock associated with loan agreement |
|
24,851 |
|
|
|
24,851 |
|
|
|
24,851 |
|
|
|
24,851 |
|
Warrants to purchase common stock associated with Danforth |
|
6,250 |
|
|
|
6,250 |
|
|
|
6,250 |
|
|
|
6,250 |
|
Total |
|
8,433,115 |
|
|
|
2,696,193 |
|
|
|
8,433,115 |
|
|
|
2,696,193 |
|
|